|
1
|
Conte MS, Pomposelli FB, Clair DG,
Geraghty PJ, McKinsey JF, Mills JL, Moneta GL, Murad MH, Powell RJ,
Reed AB, et al Society for Vascular Surgery Lower Extremity
Guidelines Writing Group; Society for Vascular Surgery, : Society
for Vascular Surgery practice guidelines for atherosclerotic
occlusive disease of the lower extremities: Management of
asymptomatic disease and claudication. J Vasc Surg. 61
(Suppl):S2.S41–41S.e1. 2015. View Article : Google Scholar
|
|
2
|
Gerhard-Herman MD, Gornik HL, Barrett C,
Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG,
Hamburg NM, Kinlay S, et al: 2016 AHA/ACC Guideline on the
Management of Patients With Lower Extremity Peripheral Artery
Disease: Executive summary: A report of the American College of
Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. J Am Coll Cardiol. 69:1465–1508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hinchliffe RJ, Brownrigg JR, Apelqvist J,
Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE
and Schaper NC; International Working Group on the Diabetic Foot, :
IWGDF guidance on the diagnosis, prognosis and management of
peripheral artery disease in patients with foot ulcers in diabetes.
Diabetes Metab Res Rev. 32 (Suppl 1):37–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jaff MR, White CJ, Hiatt WR, Fowkes GR,
Dormandy J, Razavi M, Reekers J and Norgren L: An update on methods
for revascularization and expansion of the TASC lesion
classification to include below-the-knee arteries: A supplement to
the Inter-Society Consensus for the Management of Peripheral
Arterial Disease (TASC II): The TASC Steering Comittee. Ann Vasc
Dis. 8:343–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McDermott MM: Lower extremity
manifestations of peripheral artery disease: The pathophysiologic
and functional implications of leg ischemia. Circ Res.
116:1540–1550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao
J, Liu F, Bao Y and Jia W: Serum fibroblast growth factor 21 levels
is associated with lower extremity atherosclerotic disease in
Chinese female diabetic patients. Cardiovasc Diabetol. 14:322015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aboyans V, Ricco JB, Bartelink MEL, Björck
M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S,
et al ESC Scientific Document Group, : 2017 ESC Guidelines on the
Diagnosis and Treatment of Peripheral Arterial Diseases, in
collaboration with the European Society for Vascular Surgery
(ESVS): Document covering atherosclerotic disease of extracranial
carotid and vertebral, mesenteric, renal, upper and lower extremity
arteries. Endorsed by the European Stroke Organization (ESO)The
Task Force for the Diagnosis and Treatment of Peripheral Arterial
Diseases of the European Society of Cardiology (ESC) and of the
European Society for Vascular Surgery (ESVS). Eur Heart J.
39:763–816. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patel MR, Conte MS, Cutlip DE, Dib N,
Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, et al:
Evaluation and treatment of patients with lower extremity
peripheral artery disease: Consensus definitions from Peripheral
Academic Research Consortium (PARC). J Am Coll Cardiol. 65:931–941.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chu YS, Li DX, Zhang M and Jiang TM:
Trimetazidine hydrochloride as a new treatment for patients with
peripheral vascular disease - an exploratory trial. Eur Rev Med
Pharmacol Sci. 20:188–193. 2016.PubMed/NCBI
|
|
10
|
Lawall H, Pokrovsky A, Checinski P,
Ratushnyuk A, Hamm G, Randerath O, Grieger F and Bentz JWG:
Efficacy and safety of alprostadil in patients with peripheral
arterial occlusive disease Fontaine Stage IV: Results of a placebo
controlled randomised multicentre trial (ESPECIAL). Eur J Vasc
Endovasc Surg. 53:559–566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang PP, Li SZ, Han MZ, Xiao ZJ, Yang RC,
Qiu LG and Han ZC: Autologous transplantation of peripheral blood
stem cells as an effective therapeutic approach for severe
arteriosclerosis obliterans of lower extremities. Thromb Haemost.
91:606–609. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng GY, Zhan JH, Luo JH and Cheng X:
Effect of alprostadil on wound healing of scalded rats and the
mechanism. Zhonghua Shao Shang Za Zhi. 34:380–385. 2018.(In
Chinese). PubMed/NCBI
|
|
13
|
Stary CM, Kohin S, Samaja M, Howlett RA
and Hogan MC: Trimetazidine reduces basal cytosolic Ca2+
concentration during hypoxia in single Xenopus skeletal myocytes.
Exp Physiol. 88:415–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun MZ, Liu S and Greenaway FT:
Characterization of a fibrinolytic enzyme (ussurenase) from
Agkistrodon blomhoffii ussurensis snake venom: Insights into
the effects of Ca2+ on function and structure. Biochim
Biophys Acta. 1764:1340–1348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stoner MC, Calligaro KD, Chaer RA, Dietzek
AM, Farber A, Guzman RJ, Hamdan AD, Landry GJ and Yamaguchi DJ;
Society for Vascular Surgery, : Reporting standards of the Society
for Vascular Surgery for endovascular treatment of chronic lower
extremity peripheral artery disease. J Vasc Surg. 64:e1–e21. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reinecke H, Unrath M, Freisinger E,
Bunzemeier H, Meyborg M, Lüders F, Gebauer K, Roeder N, Berger K
and Malyar NM: Peripheral arterial disease and critical limb
ischaemia: Still poor outcomes and lack of guideline adherence. Eur
Heart J. 36:932–938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horie T, Kimura T and Ono K: Emerging
novel biomarkers for arteriosclerosis obliterans. J Atheroscler
Thromb. 23:171–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hoshino J, Ubara Y, Hara S, Sogawa Y,
Suwabe T, Higa Y, Nakanishi S, Sawa N, Katori H, Takemoto F, et al:
Quality of life improvement and long-term effects of peripheral
blood mononuclear cell transplantation for severe arteriosclerosis
obliterans in diabetic patients on dialysis. Circ J. 71:1193–1198.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bandinelli F, Bartoli F, Perfetto E, Del
Rosso A, Moggi-Pignone A, Guiducci S, Cinelli M, Fatini C, Generini
S, Gabrielli A, et al: The fibrinolytic system components are
increased in systemic sclerosis and modulated by alprostadil
(alpha1 ciclodestryn). Clin Exp Rheumatol. 23:671–677.
2005.PubMed/NCBI
|
|
20
|
Saigawa T, Kato K, Ozawa T, Toba K,
Makiyama Y, Minagawa S, Hashimoto S, Furukawa T, Nakamura Y, Hanawa
H, et al: Clinical application of bone marrow implantation in
patients with arteriosclerosis obliterans, and the association
between efficacy and the number of implanted bone marrow cells.
Circ J. 68:1189–1193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Z, Chen JM, Huang H, Kuznicki M, Zheng
S, Sun W, Quan N, Wang L, Yang H, Guo HM, et al: The protective
effect of trimetazidine on myocardial ischemia/reperfusion injury
through activating AMPK and ERK signaling pathway. Metabolism.
65:122–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rehberger-Likozar A and Šebeštjen M:
Influence of trimetazidine and ranolazine on endothelial function
in patients with ischemic heart disease. Coron Artery Dis.
26:651–656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lacroix R, Sabatier F, Mialhe A, Basire A,
Pannell R, Borghi H, Robert S, Lamy E, Plawinski L, Camoin-Jau L,
et al: Activation of plasminogen into plasmin at the surface of
endothelial microparticles: A mechanism that modulates angiogenic
properties of endothelial progenitor cells in vitro. Blood.
110:2432–2439. 2007. View Article : Google Scholar : PubMed/NCBI
|
